Saum Ghodoussipour, MD

Considering the toxicity burden of dual checkpoint inhibition for adjuvant RCC, Saum Ghodoussipour, MD, posited potential alternatives in the space.

Saum Ghodoussipour, MD, PhD, dissected the contrasting outcomes between adjuvant durvalumab plus tremelimumab compared with durvalumab alone in RCC.